NCT03195049

Brief Summary

Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2018

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 15, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 22, 2017

Completed
10 months until next milestone

Study Start

First participant enrolled

April 15, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2019

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2019

Completed
Last Updated

June 22, 2017

Status Verified

June 1, 2017

Enrollment Period

1 year

First QC Date

June 15, 2017

Last Update Submit

June 21, 2017

Conditions

Keywords

hyperbilirubinemiakernicterus

Outcome Measures

Primary Outcomes (1)

  • serum bilirubin estimation

    estimation of serum bilirubin

    2 days

Study Arms (2)

blood group

EXPERIMENTAL

blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .

Diagnostic Test: blood group,complete blood count

serum bilirubin estimation

EXPERIMENTAL

estimation of serum bilirubin before, during and after the procedure of exchange transfusion .

Diagnostic Test: blood group,complete blood count

Interventions

measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion

Also known as: measure levels of total and direct bilirubin
blood groupserum bilirubin estimation

Eligibility Criteria

Age1 Day - 4 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • All preterm and full term neonates who need exchange transfusion

You may not qualify if:

  • Neonatal sepsis
  • Congenital anomalies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007 Jul;120(1):27-32. doi: 10.1542/peds.2006-2910.

  • Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am. 2004 Aug;51(4):843-61, vii. doi: 10.1016/j.pcl.2004.03.011.

MeSH Terms

Conditions

KernicterusHyperbilirubinemia

Interventions

Blood Grouping and CrossmatchingBlood Cell Count

Condition Hierarchy (Ancestors)

Brain Diseases, MetabolicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesErythroblastosis, FetalHematologic DiseasesHemic and Lymphatic DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic DiseasesImmune System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hematologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHistocompatibility TestingImmunologic TestsBlood BankingBlood PreservationTissue PreservationPreservation, BiologicalTherapeuticsInvestigative TechniquesImmunologic TechniquesCell CountCytological TechniquesCell Physiological PhenomenaBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Study Officials

  • Hanaa Ab Mohamed, Professor

    Assiut University

    STUDY CHAIR

Central Study Contacts

Hanaa Ab Mohamed, Professor

CONTACT

Safwat Mo Abdel-Aziz, Lecturer

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 15, 2017

First Posted

June 22, 2017

Study Start

April 15, 2018

Primary Completion

April 15, 2019

Study Completion

September 15, 2019

Last Updated

June 22, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share